Supplementary Figure S5 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Q: What type of study is this?

This is a Quantitative Study study.

Jack C. Stromatt; Eman Ahmed; Thomas Drabison; Mahesh R. Nepal; Anika T. Chowdhury; Shelley Orwick; Daelynn R. Buelow; Eric D. Eisenmann; Kevin M. Huang; Alex Sparreboom; Sharyn D. Baker

doi:10.1158/2767-9764.30111353

September 12, 2025Open Access

Supplementary Figure S5 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

View Full Paper

Ask AI

Bookmark

Share

Key Points

TL-895 demonstrated significant activity against LYN kinase, suggesting a potential drug-drug interaction.
In KINOMEscan assays, TL-895's data indicated mean values and standard deviation across two biological replicates.
Nilotinib was used as a positive control to assess TL-895's efficacy against LYN kinase activity.
The study emphasizes the relevance of post-translational regulation in understanding drug interactions with OATP1B.

Implication

Analysis reveals TL-895's activity on LYN kinase, highlighting its drug-drug interaction potential with OATP1B.

Abstract

Activity of TL-895 on LYN kinase. KINOMEscan activity of TL-895 and nilotinib, a positive control, against LYN kinase, a post-translational regulator of OATP1B transporter activity. Data represent mean values (symbols) and SD (error bars) of 2 biological replicate experiments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stromatt et al. (2025) studied this question.

synapsesocial.com/papers/68d44c5531b076d99fa5610d https://doi.org/10.1158/2767-9764.30111353

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S5 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S5 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading